Are MELD and MELDNa Still Reliable Tools to Predict Mortality on the Liver Transplant Waiting List?

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Tejedor, M
  • Selzner, N

Grupos

Abstract

Liver transplantation is the only curative treatment for end-stage liver disease. Unfortunately, the scarcity of donor organs and the increasing pool of potential recipients limit access to this life-saving procedure. Allocation should account for medical and ethical factors, ensuring equal access to transplantation regardless of recipient's gender, race, religion, or income. Based on their short-term prognosis prediction, model for end-stage liver disease (MELD) and MELD sodium (MELDNa) have been widely used to prioritize patients on the waiting list for liver transplantation resulting in a significant decrease in waiting list mortality/removal. Recent concern has been raised regarding the prognostic accuracy of MELD and MELDNa due, in part, to changes in recipients' profile such as body mass index, comorbidities, and general condition, including nutritional status and cause of liver disease, among others. This review aims to provide a comprehensive view of the current state of MELD and MELDNa advantages and limitations and promising alternatives. Finally, it will explore future options to increase the donor pool and improve donor-recipient matching.

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Datos de la publicación

ISSN/ISSNe:
0041-1337, 1534-6080

TRANSPLANTATION  LIPPINCOTT WILLIAMS & WILKINS

Tipo:
Article
Páginas:
2122-2136
PubMed:
35594480
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
1,407 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 30

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • INTERNATIONAL NORMALIZED RATIO; RACE/ETHNICITY-SPECIFIC DISPARITIES; MACHINE-LEARNING ALGORITHMS; GLOMERULAR-FILTRATION-RATE; SERUM SODIUM; HEPATOCELLULAR-CARCINOMA; PROTHROMBIN TIME; GENDER DISPARITY; DISEASE SCORE; LOW MODEL

Campos de Estudio

Cita

Compartir